Maxim Initiates Coverage of Pluristem Therapeutics Inc. with a Buy Rating and ...
MarketWatch (press release)
Kolbert points to Pluristem's recently signed license with United Therapeutics Corporation (NASDAQ:UTHR) for the development of PLX cells in pulmonary disorders, which initiated at $7M and includes an additional $37.5M in regulatory milestones. Maxim ...

and more »


More...